BenevolentAI Investor Conference Presentation Deck
Target validation in colon tissue
from ulcerative colitis patients
Inflamed colonic mucosa biopsies from UC patients
• Disease phenotype retained with high basal cytokine release
• Readouts: IL6 and IL8 - key mediators of UC pathology
Tissue samples treated with:
• Target-selective tool compound (BEN-3218)
• Positive controls - prednisolone and tofacitinib
Selective target inhibition showed comparable
reduction of IL-6 and IL-8 to the positive controls
Validated as a target with a novel
mechanism of action for ulcerative colitis
(w/6d)9-11
20000
15000
10000
5000
0
Endoscopic
Biopsy from UC
patients
IL-8(pg/ml)
DMSO Prednisolone Tofacitinib BEN-3218
Inflammatory cytokine
measurement
30000
20000
Colonic mucosa
organ culture and
compound treatment
10000
1
DMSO
Prednisolone Tofacitinib BEN-3218
Benevolent 22View entire presentation